EPSRC Centre for Doctoral Training in Bioprocess Engineering Leadership (Complex Biological Products Manufacture)

英国政府对生命科学产业战略的支持（贝尔报告，2017年）认识到开发新药对促进英国经济增长的重要性。这方面的例子包括治疗癌症的新抗体疗法、控制传染病传播的新疫苗，以及治疗失明和痴呆等以前无法治疗的疾病的细胞和基因疗法的出现。生物加工技术是下一代复杂生物产品安全、经济、环保生产的基础。它们有助于将生命科学发现迅速转化为新药，造福于需要它们的患者。然而，最近的报告强调，特定的技能短缺限制了英国利用这些领域的财富和创造就业机会的能力。他们强调需要“更多受过先进制造培训的个人”，以及具有生物加工技能的个人，他们可以解决“使用生物材料扩大生产的挑战”。UCL EPSRC生物过程工程领导CDT在为研究生科学家和工程师提供工业所需的生物处理技能方面取得了成功的记录。它将提供一个“全生物过程”的培训主题，以核心发酵和下游加工技能为基础的药物制造。该方案旨在加速毕业生进行博士研究，并建立一个多学科研究队伍；这将通过与爱尔兰的合成和固体制药中心（SSPC）和国家生物工艺研究和培训研究所（NIBRT）的伙伴关系得到加强。研究项目将与领先的英国和国际公司合作进行。对CDT的持续需求可以从以下事实得到证明：96%的毕业生已经进入了相关的生物产业职业，许多人现在处于高级领导职位。下一代分子或细胞药物将越来越复杂，因此难以描述。这意味着它们将更加难以大规模生产，从而更难以确保它们不仅安全，而且具有成本效益。这项提议将使CDT能够培训未来的生物产业领导者，他们拥有制造下一代复杂生物药物所需的理论知识和实践和商业技能。这将通过使每个研究人员与国际领先的研究团队保持一致，并制定个人培训和职业发展计划来实现。通过这种方式，CDT将有助于英国生物过程利用工业的未来成功。

The UK government's support for the Life Sciences Industry Strategy (Bell Report, 2017) recognises the importance of developing new medicines to facilitate UK economic growth. Examples include new antibody therapies for the treatment of cancer, new vaccines to control the spread of infectious diseases and the emergence of cell and gene therapies to cure previously untreatable conditions such as blindness and dementia. Bioprocessing skills underpin the safe, cost-effective and environmentally friendly manufacture of this next generation of complex biological products. They facilitate the rapid translation of life science discoveries into the new medicines that will benefit the patients that need them.Recent reports, however, highlight specific skills shortages that constrain the UK's capacity to capitalise on opportunities for wealth and job creation in these areas. They emphasise the need for 'more individuals trained in advanced manufacturing' and for individuals with bioprocessing skills who can address the 'challenges with scaling-up production using biological materials'.The UCL EPSRC CDT in Bioprocess Engineering Leadership has a successful track record of equipping graduate scientists and engineers with the bioprocessing skills needed by industry. It will deliver a 'whole bioprocess' training theme based around the core fermentation and downstream processing skills underpinning medicines manufacture. The programme is designed to accelerate graduates into doctoral research and to build a multidisciplinary research cohort; this will be enhanced through a partnership with the Synthesis and Solid State Pharmaceutical Centre (SSPC) and the National Institute for Bioprocess Research and Training (NIBRT) in Ireland. Research projects will be carried out in partnership with leading UK and international companies. The continued need for the CDT is evidenced by the fact that 96% of previous graduates have progressed to relevant bioindustry careers and many are now in senior leadership positions.The next generation of molecular or cellular medicines will be increasingly complex and hence difficult to characterise. This means they will be considerably more difficult to manufacture at large scale making it harder to ensure they are not only safe but also cost-effective. This proposal will enable the CDT to train future bioindustry leaders who possess the theoretical knowledge and practical and commercial skills necessary to manufacture this next generation of complex biological medicines. This will be achieved by aligning each researcher with internationally leading research teams and developing individual training and career development programmes. In this way the CDT will contribute to the future success of the UK's bioprocess-using industries.